|
| Figure 1: AS-PCR Results for Clinical Study GS-US-196-0101. Y448H AS-PCR was performed on baseline samples from 65 treatment naive HCV-infected genotype 1 patients. 62/65 patients had detectable Y448H at baseline. 20/36 patients in cohorts that received 8 day Tegobuvir (GS-9190) monotherapy underwent AS-PCR analysis of longitudinal samples. Since 3/20 patients failed the assay and 1/20 patient did not have samples available, AS-PCR results were obtained for 16/20 patients, including 1 placebo, to estimate pre-existing Y448H BL levels. |
